Slashing patient no-show rates with an EHR-integrated SaaS platform that arranges non-emergency medical transportation. Better patient outcomes, better provider bottomlines.  Strategic investments from Zoll Medical & Johns Hopkins. Operations throughout the US, multiple health system customers and channel partners.
Forest Devices’ novel AI-empowered technology helps first-responders objectively determine whether a patient is experiencing an ischemic stroke, to transport them to the RIGHT stroke treatment center the FIRST time.  Time = Brain.  Secured partnership with Alberta Health to complete pivotal trial, which could lead the way to the mandated use of Forest Devices’ technology throughout the province of Alberta, Canada.   Grand Prize Winner, 2019, Med Tech Innovator Showcase.
Improving infection control by helping workers visualize surface decontamination in real time.  Applications across multiple sectors including healthcare, transportation, educational facilities & other commercial properties. Winner of Harvard President’s Innovation Challenge; Lemelson-MIT Student Prize; USAID Fighting Ebola Grand Challenge.
Johns Hopkins Medical spin-out company, Vixiar, has developed a point-of-care, hand-held, non-invasive, remote monitoring device to detect the earliest subclinical signs of heart failure, the #1 hospital diagnosis in patients 65 yrs+.  Among 4 finalists selected by Philips Healthcare in 2019 for their Patient Monitoring & Patient Care Analytics program.
HIPAA-compliant, digital patient engagement platform for use before, during & post-hospital procedures to optimize patient outcomes.  Integrated into the major EHRs: Epic, Cerner & Allscripts.  15+ studies show ↓72% readmissions, ↓1-2 days hospital length of stats, ↓$2,300+ costs/patient.  Key partnership with Wolters Kluwer, a global leader in patient and provider education.
FDA-approved, CE mark minimally invasive device for pelvic organ prolapse, a prevalent condition impacting millions of peri/menopausal women globally.  Clinical studies completed for up to 4 years post-insertion. Safe, effective.  Approved by multiple U.S. hospital value-add committees.  Commercial stage. Available in the US & EU.
Bringing the full suite of Intensive Care support remotely to small and mid-sized hospitals that require it the most, from Intensivists to technology and predictive analytics.  Greater support can equal life-saving outcomes for patients.  Management with relevant prior exits to Teladoc.
Promoting healthier eating, Smoodi has developed a proprietary, robotics-aided device that both purees customizable choices of healthy fruits & boosters into smoothies and self-cleans.  Small footprint, taking 2 square feet of benchtop space; like a coffee machine for smoothies.
A Stanford Biodesign-spin out, Empirical Spine has developed a motion-preserving lumbar spinal implant for sciatica patients suffering from degenerative spondylolisthesis, the most common diagnosis leading to lumbar spinal fusion.  The condition impacts the aging population and has a female : male prevalence of 3:1.  CE Mark, implanted in 2000 EU patients.  Completed enrollment of US pivotal IDE clinical trial in July 2020, to support a FDA PMA clearance.
Dynamicare Health of Boston, MA is dedicated to making addiction recovery support more widely accessible at affordable rates through the power of digital health.  The company’s approach is based on evidence-based contingency management psychotherapy which provides positive reward reinforcement, proven to improve abstinence by 2x-3x.  Dynamicare’s success against the meth epidemic is featured in the NYTimes here (10/27/2020).
Bendit Technologies has developed a series of revolutionary microcatheters with unique bendability, steerability & unprecedented torque. Their tools enable interventional surgeons to navigate thru tortuous & challenging anatomies to reach clots, tumors and other vascular pathologies in fastest times.  First generation has been FDA-approved, received CE mark.  Bendit’s microcatheters have successfully been used in a dozen+ human peripheral and neurointerventional cases.
FDA-approved, safe tissue stimulation device, StimSite, triggers the natural movements of hard-to-locate critical structures so surgeons can easily identify them to operate safely & with confidence. Allotrope’s StimSite is conveniently integrated into existing instruments and robotic platforms, so workflow is maintained. Allotrope is a Y Combinator & MedTech Innovator alum – more here.
A spin-out from MIT, Landsdowne Labs was established to develop a life-saving coating, the ChildLok, around button batteries to deactivate the necrotic and potentially fatal sequelae in young children who may accidentally swallow them. The invention was created by a world-class team who cofounded the company, including Bob Langer, Jeff Karp, Bryan Laulicht & Jonah Myerberg. Led by Cofounder & CEO Melissa Fensterstock, Landsdowne stands to create a new industry standard in battery safety.
A spin-out from Columbia University, Epibone is a clinical-stage regenerative medicine company utilizing autologous mesenchymal stem cells to reconstruct bone and cartilage.  The company has raised nearly $37 Mill USD to support its pipelines, including a Phase I/II trial for craniofacial bone reconstruction and various cartilage R&D programs.
Eyedaptic has developed an FDA Class I Exempt natural vision software embedded in wearable augmented reality (AR) glasses, to improve the vision and quality of life for those suffering from age-related macular degeneration (AMD).  This is a condition that impacts hundreds of millions globally & for which there is no cure.  Eyedaptics’ cutting-edge technology further provides a personalized pathway to vision improvement based on its software capabilities.’s mission is to match consumers with the right health insurance plan the first time around.  Millions disenroll from health plans annually, due unexpected & unaffordable out-of-pocket costs and care that does not entirely meet their health needs.  These can leave them financially stressed, with inadequate care & highly frustrated.  Health plans spend hundreds of millions to enroll new members & recoup lost ones.’s uniquely vetted consumer queries & end-to-end SaaS platform provide a comprehensive solution for both sides of this critical marketplace.
Biotia, Inc. combines next-generation sequencing with AI to identify microbes underlying infectious diseases.  Their rapid, high-throughput and agnostic approach enables treatment of patients with the right solution, the first time, considers resistance to therapy and identification of mutant variants.  Identification of microbes can further propel the development of novel, effective therapies.  With their unique CLIA-certified lab in NY, Biotia is advantageously positioned to penetrate the US infectious disease diagnostics market.
For inquiries, please contact us at